Identification

Name
Clevidipine
Accession Number
DB04920
Type
Small Molecule
Groups
Approved
Description

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Structure
Thumb
Synonyms
  • Clevidipine butyrate
External IDs
H-324/38
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CleviprexEmulsion.5 mg/mLIntravenousThe Medicines Company2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousChiesi Pharmaceuticals Inc.2008-09-15Not applicableUs
CleviprexEmulsion0.5 mgIntravenousChiesi Farmaceutici S.P.A.Not applicableNot applicableCanada
CleviprexEmulsion.5 mg/mLIntravenousChiesi Pharmaceuticals Inc.2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousFresenius Kabi Austria Gmb H2008-09-15Not applicableUs
CleviprexEmulsion.5 mg/mLIntravenousChiesi Pharmaceuticals Inc.2008-09-15Not applicableUs
Categories
UNII
19O2GP3B7Q
CAS number
167221-71-8
Weight
Average: 456.316
Monoisotopic: 455.090242887
Chemical Formula
C21H23Cl2NO6
InChI Key
KPBZROQVTHLCDU-UHFFFAOYSA-N
InChI
InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
IUPAC Name
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
SMILES
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Pharmacodynamics

Clevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output.

Mechanism of action

Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.

TargetActionsOrganism
UVoltage-dependent L-type calcium channel subunit alpha-1FNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1SNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1DNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1CNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

>99.5%

Metabolism

Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

Route of elimination

urine 63-74%, feces 7-22%

Half life

1 minute

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Clevidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Clevidipine.Vet Approved
AbirateroneThe serum concentration of Clevidipine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Clevidipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Clevidipine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Clevidipine.Approved
AmiodaroneThe metabolism of Clevidipine can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Clevidipine.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Clevidipine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clevidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Clevidipine.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Clevidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Clevidipine.Approved
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clevidipine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clevidipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Clevidipine.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Clevidipine.Approved
AtomoxetineThe metabolism of Clevidipine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Clevidipine is combined with Atosiban.Approved, Investigational
Atracurium besylateClevidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Clevidipine can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Clevidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Clevidipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Clevidipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clevidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clevidipine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Clevidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Clevidipine.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Clevidipine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Clevidipine.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.Approved
BortezomibThe metabolism of Clevidipine can be decreased when combined with Bortezomib.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Clevidipine.Experimental
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Clevidipine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clevidipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Clevidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.Approved
BunazosinBunazosin may increase the hypotensive activities of Clevidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clevidipine.Approved, Investigational
BupropionThe metabolism of Clevidipine can be decreased when combined with Bupropion.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Clevidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Clevidipine.Approved
CaffeineThe metabolism of Clevidipine can be decreased when combined with Caffeine.Approved
Calcium AcetateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Clevidipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Clevidipine.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Clevidipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.Approved
CarbamazepineThe metabolism of Clevidipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clevidipine.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Clevidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Clevidipine.Approved
CelecoxibThe metabolism of Clevidipine can be decreased when combined with Celecoxib.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Clevidipine.Approved
ChloroquineThe metabolism of Clevidipine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Clevidipine.Approved
ChlorpromazineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clevidipine.Approved
CholecalciferolThe metabolism of Clevidipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Clevidipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clevidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clevidipine.Approved
CimetidineThe serum concentration of Clevidipine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Clevidipine can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Clevidipine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Clevidipine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Clevidipine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clevidipine.Approved, Investigational
ClomipramineThe metabolism of Clevidipine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Clevidipine.Approved, Vet Approved
ClozapineThe metabolism of Clevidipine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Clevidipine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clevidipine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Clevidipine.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Clevidipine.Investigational
CyclosporineThe metabolism of Clevidipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Clevidipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Clevidipine.Investigational
DarifenacinThe metabolism of Clevidipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clevidipine can be increased when it is combined with Darunavir.Approved
DeferasiroxThe serum concentration of Clevidipine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clevidipine can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clevidipine.Approved
DesipramineThe metabolism of Clevidipine can be decreased when combined with Desipramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clevidipine.Approved, Vet Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Clevidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clevidipine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Clevidipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Clevidipine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.Approved
DosulepinThe metabolism of Clevidipine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Clevidipine.Approved
DronedaroneThe metabolism of Clevidipine can be decreased when combined with Dronedarone.Approved
DuloxetineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Clevidipine.Approved
EfavirenzThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Clevidipine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Clevidipine.Approved, Investigational
EliglustatThe metabolism of Clevidipine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Clevidipine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Clevidipine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Clevidipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Clevidipine.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Clevidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clevidipine.Approved, Investigational
FluconazoleThe serum concentration of Clevidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Clevidipine.Approved
FluoxetineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Clevidipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Clevidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clevidipine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Clevidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Clevidipine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.Approved, Investigational
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Clevidipine.Experimental
HaloperidolThe metabolism of Clevidipine can be decreased when combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Clevidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clevidipine.Approved, Vet Approved
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Clevidipine.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Clevidipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Clevidipine.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Clevidipine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Clevidipine.Investigational
ImipramineThe metabolism of Clevidipine can be decreased when combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.Approved
IndinavirThe metabolism of Clevidipine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Clevidipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Clevidipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Clevidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clevidipine.Approved, Vet Approved
IsoniazidThe metabolism of Clevidipine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clevidipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clevidipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Clevidipine.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Clevidipine.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Clevidipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Clevidipine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Clevidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clevidipine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clevidipine.Approved, Investigational
LevodopaClevidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Clevidipine.Approved, Investigational
LidocaineThe metabolism of Clevidipine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.Approved, Investigational
LobeglitazoneThe metabolism of Clevidipine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Clevidipine.Approved, Investigational
LopinavirThe metabolism of Clevidipine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Clevidipine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Lovastatin.Approved, Investigational
LumefantrineThe metabolism of Clevidipine can be decreased when combined with Lumefantrine.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe metabolism of Clevidipine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Clevidipine.Approved, Nutraceutical, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Clevidipine.Experimental
MethadoneThe metabolism of Clevidipine can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Clevidipine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Clevidipine.Approved
MethotrimeprazineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Clevidipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Clevidipine.Approved, Investigational
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Clevidipine.Experimental
MexiletineThe metabolism of Clevidipine can be decreased when combined with Mexiletine.Approved
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Clevidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Clevidipine.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Clevidipine can be decreased when combined with Midostaurin.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Clevidipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.Approved
MirabegronThe metabolism of Clevidipine can be decreased when combined with Mirabegron.Approved
MivacuriumClevidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Clevidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clevidipine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Clevidipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Clevidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Clevidipine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.Approved
NafcillinThe metabolism of Clevidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clevidipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Clevidipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Clevidipine.Approved, Investigational
NevirapineThe metabolism of Clevidipine can be decreased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clevidipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Clevidipine.Approved, Investigational
NicotineThe metabolism of Clevidipine can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Clevidipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Clevidipine.Investigational
NilotinibThe metabolism of Clevidipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Clevidipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clevidipine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clevidipine.Approved, Investigational
NitroprussideClevidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Clevidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Clevidipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clevidipine.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.Approved, Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Clevidipine.Experimental
OsimertinibThe serum concentration of Clevidipine can be decreased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Clevidipine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clevidipine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clevidipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Clevidipine.Investigational
PanobinostatThe serum concentration of Clevidipine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.Approved
ParoxetineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Clevidipine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Clevidipine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Clevidipine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Clevidipine.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Clevidipine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Clevidipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clevidipine.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Clevidipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clevidipine.Approved, Investigational
PitavastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Clevidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Clevidipine.Approved, Investigational
PravastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Pravastatin.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Clevidipine.Approved
PrimidonePrimidone may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
PromazineThe metabolism of Clevidipine can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clevidipine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.Approved, Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Clevidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Clevidipine.Approved
QuinineThe metabolism of Clevidipine can be decreased when combined with Quinine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Clevidipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.Approved
RanolazineThe metabolism of Clevidipine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumClevidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clevidipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clevidipine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.Approved, Investigational
RifabutinThe serum concentration of Clevidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Clevidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clevidipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Clevidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Clevidipine is combined with Riociguat.Approved
RisperidoneClevidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Clevidipine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Clevidipine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Clevidipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clevidipine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Clevidipine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Clevidipine.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Clevidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clevidipine.Approved, Vet Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clevidipine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clevidipine.Approved, Investigational, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Clevidipine.Approved
SertralineThe metabolism of Clevidipine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clevidipine.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Clevidipine.Approved
SimeprevirThe metabolism of Clevidipine can be decreased when combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Clevidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clevidipine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Clevidipine.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.Approved
StiripentolThe metabolism of Clevidipine can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clevidipine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Clevidipine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.Approved, Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Clevidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Clevidipine.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Clevidipine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Clevidipine.Approved
TerbinafineThe metabolism of Clevidipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Clevidipine.Approved
TeriflunomideThe serum concentration of Clevidipine can be decreased when it is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clevidipine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Clevidipine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
ThioridazineThe metabolism of Clevidipine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Clevidipine.Approved
TiclopidineThe metabolism of Clevidipine can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Clevidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Clevidipine.Approved
TipranavirThe metabolism of Clevidipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Clevidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clevidipine.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Clevidipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Clevidipine.Approved, Vet Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.Approved
TranylcypromineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Clevidipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Clevidipine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Clevidipine.Approved, Investigational
UbidecarenoneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Ubidecarenone.Approved, Experimental
UrapidilUrapidil may increase the hypotensive activities of Clevidipine.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.Approved, Investigational
VenlafaxineThe metabolism of Clevidipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Clevidipine.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Clevidipine.Approved, Investigational
ZiprasidoneThe metabolism of Clevidipine can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Clevidipine can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Grapefruit Juice

References

General References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
  2. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
  3. Wang QD, Segawa D, Ericsson H, Sjoquist PO, Johansson L, Ryden L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002 Aug;40(2):228-34. [PubMed:12131552]
  4. Stephens CT, Jandhyala BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002 May;24(4):301-13. [PubMed:12069360]
External Links
KEGG Drug
D08892
PubChem Compound
153994
PubChem Substance
175426904
ChemSpider
135722
ChEBI
135738
ChEMBL
CHEMBL1237132
Wikipedia
Clevidipine
ATC Codes
C08CA16 — Clevidipine
AHFS Codes
  • 24:28.08 — Dihydropyridines
FDA label
Download (381 KB)
MSDS
Download (568 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHypertensive1
2Unknown StatusTreatmentCerebral Aneurysms / Subarachnoid Hemorrhage / Vasospasm, Intracranial1
2Unknown StatusTreatmentHypertensive / Subarachnoid Hemorrhage1
2, 3CompletedTreatmentNeuromuscular Scoliosis1
3CompletedTreatmentHeart Failure, Unspecified / Hypertensive1
3CompletedTreatmentHemorrhage / Hypertensive1
3CompletedTreatmentHypertensive6
4CompletedDiagnosticPulmonary Hypertension (PH)1
4CompletedTreatmentEpilepsies / Hypertensive / Neoplasms, Brain1
4RecruitingTreatmentNontraumatic Intracerebral Hemorrhage, Multiple Localized1
4TerminatedTreatmentAortic Aneurysms / Aortic Diseases1
4Unknown StatusTreatmentHypertensive / Intracranial Hemorrhages / Subarachnoid Hemorrhage1
4Unknown StatusTreatmentPediatric Perioperative Blood Pressure Management1
4WithdrawnTreatmentHypertensive2
Not AvailableWithdrawnTreatmentAorta Aneurysm / Dissection of Aorta1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
EmulsionIntravenous.5 mg/mL
EmulsionIntravenous0.5 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5739152No1995-04-142015-04-14Us
US5856346No2001-01-052021-01-05Us
US8658676No2011-10-102031-10-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00267 mg/mLALOGPS
logP4.98ALOGPS
logP4.09ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity113.93 m3·mol-1ChemAxon
Polarizability45.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9887
Blood Brain Barrier-0.5892
Caco-2 permeable+0.6566
P-glycoprotein substrateSubstrate0.5787
P-glycoprotein inhibitor IInhibitor0.8948
P-glycoprotein inhibitor IINon-inhibitor0.6827
Renal organic cation transporterNon-inhibitor0.8312
CYP450 2C9 substrateNon-substrate0.8879
CYP450 2D6 substrateNon-substrate0.8693
CYP450 3A4 substrateSubstrate0.693
CYP450 1A2 substrateInhibitor0.6871
CYP450 2C9 inhibitorInhibitor0.6818
CYP450 2D6 inhibitorNon-inhibitor0.8455
CYP450 2C19 inhibitorInhibitor0.7456
CYP450 3A4 inhibitorInhibitor0.9187
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9098
Ames testNon AMES toxic0.7527
CarcinogenicityNon-carcinogens0.8407
BiodegradationNot ready biodegradable0.9403
Rat acute toxicity2.6248 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7841
hERG inhibition (predictor II)Non-inhibitor0.8148
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0059-0015900000-5d813bb035601f752e65
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000l-0019000000-3e3b6549a7821bc27951

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Tricarboxylic acids and derivatives / Dichlorobenzenes / Acylals / Fatty acid esters / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Acetals
show 8 more
Substituents
Dihydropyridinecarboxylic acid derivative / Tricarboxylic acid or derivatives / 1,2-dichlorobenzene / Chlorobenzene / Acylal / Fatty acid ester / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Ericsson H, Tholander B, Regardh CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37. [PubMed:10072476]

Drug created on October 21, 2007 16:23 / Updated on November 22, 2017 12:36